ABSTRACT
INTRODUCTION/TRIAL RATIONALE The current standard of care for patients with symptomatic severe mitral regurgitation (MR) or asymptomatic severe MR with evidence of left ventricular (LV) dysfunction or dilation is surgical intervention (1). A sizable proportion of patients with severe symptomatic MR are not referred for an operation due to elevated surgical risk. Patients with previous coronary artery bypass graft surgery, multiple comorbidities, and older age constitute the majority of this group. Endovascular therapies for the treatment of severe mitral regurgitation have been developed as an alternative approach to surgical repair in highrisk patients.
